KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Cash (2016 - 2025)

Historic Change in Cash for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $140.0 million.

  • Vertex Pharmaceuticals' Change in Cash rose 12071.31% to $140.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $515.6 million, marking a year-over-year increase of 10888.95%. This contributed to the annual value of $515.6 million for FY2025, which is 10888.95% up from last year.
  • Vertex Pharmaceuticals' Change in Cash amounted to $140.0 million in Q4 2025, which was up 12071.31% from -$34.2 million recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Change in Cash registered a high of $1.3 billion during Q4 2022, and its lowest value of -$4.6 billion during Q2 2024.
  • In the last 5 years, Vertex Pharmaceuticals' Change in Cash had a median value of $252.8 million in 2021 and averaged -$45.1 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Change in Cash soared by 55496.28% in 2022 and then crashed by 63373.75% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Change in Cash (Quarter) stood at $519.9 million in 2021, then skyrocketed by 156.78% to $1.3 billion in 2022, then crashed by 155.75% to -$744.3 million in 2023, then rose by 9.19% to -$675.9 million in 2024, then surged by 120.71% to $140.0 million in 2025.
  • Its Change in Cash stands at $140.0 million for Q4 2025, versus -$34.2 million for Q3 2025 and $296.6 million for Q2 2025.